LAVA Therapeutics
LAVA Therapeutics
LVTX
NASDAQ
1.75
USD
76.77%
About
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 47.7K |
| Three Month Average Volume | 1.4M |
| High Low | |
| Fifty-Two Week High | 6.47 USD |
| Fifty-Two Week Low | 1.131 USD |
| Fifty-Two Week High Date | 29 Feb 2024 |
| Fifty-Two Week Low Date | 30 Oct 2023 |
| Price and Volume | |
| Current Price | 1.75 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -15.91% |
| Thirteen Week Relative Price Change | -27.65% |
| Twenty-Six Week Relative Price Change | -27.66% |
| Fifty-Two Week Relative Price Change | -21.10% |
| Year-to-Date Relative Price Change | -6.47% |
| Price Change | |
| One Day Price Change | -4.37% |
| Thirteen Week Price Change | -22.57% |
| Twenty-Six Week Price Change | -20.45% |
| Five Day Price Change | -7.41% |
| Fifty-Two Week Price Change | -1.13% |
| Year-to-Date Price Change | 10.76% |
| Month-to-Date Price Change | -18.22% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.94674 USD |
| Book Value Per Share (Most Recent Quarter) | 1.63051 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.94674 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.63051 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.97573 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.25321 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.27408 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.57015 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.8976 USD |
| Normalized (Last Fiscal Year) | -1.57015 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.57015 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.8976 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.57015 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.8976 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.63539 USD |
| Cash Per Share (Most Recent Quarter) | 3.30072 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.52234 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.85351 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.00352 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -366 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -323.30% |
| Pretax Margin (Last Fiscal Year) | -615.97% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 48.56% |
| Gross Margin (Trailing Twelve Months) | 97.78% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -638.99% |
| Operating Margin (Trailing Twelve Months) | -371.48% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -620.09% |
| Net Profit Margin (Trailing Twelve Months) | -326.89% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -69.51% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | 24.59% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 35.97% |
| EPS Change (Trailing Twelve Months) | 42.03% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -80,637,000 |
| Net Debt (Last Fiscal Year) | -89,258,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 7 |
| Price to Sales (Trailing Twelve Months) | 6 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 1 |
| Long Term Debt to Equity (Most Recent Quarter) | 1 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 7 |
| Current Ratio (Most Recent Quarter) | 6 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -39,702,000 |
| Free Cash Flow (Trailing Twelve Months) | -27,087,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 12 |
| Total Debt to Equity (Most Recent Quarter) | 14 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -34.25% |
| Return on Assets (Trailing Twelve Months) | -22.51% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -61.18% |
| Return on Equity (Trailing Twelve Months) | -45.30% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -40.31% |
| Return on Investment (Trailing Twelve Months) | -27.11% |
| Return on Investment (5 Year) | -99,999.99% |